%0 Journal Article
%T Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause.
%A Roberts MZ
%A Andrus MR
%J Expert Opin Pharmacother
%V 0
%N 0
%D 2024 Jul 2
%M 38953697
%F 4.103
%R 10.1080/14656566.2024.2375039
%X <B>UNASSIGNED: </B>During menopause the majority of women experience vasomotor symptoms which may lead to several untoward effects and negatively impact quality of life. Fezolinetant, a, novel agent directly targeting the underlying pathophysiology of menopause-associated vasomotor symptoms offers an alternative to hormonal therapies for which many patients have a contraindication or unwillingness to take due to safety concerns.<BR><B>UNASSIGNED: </B>This review summarizes key pharmacologic, pharmacokinetic, and pharmacodynamic parameters of fezolinetant along with efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications evaluating the efficacy and safety of fezolinetant was conducted using PubMed and EMBASE databases. A review of registered trials in clinicaltrials.gov was evaluated to identify ongoing studies.<BR><B>UNASSIGNED: </B>Placebo-controlled studies demonstrated that fezolinetant led to a statistically significant reduction in vasomotor symptom frequency and severity among patients with moderate to severe vasomotor symptoms. The most common adverse event is headache (5-10%) and no serious safety signals have been noted. Direct head-to-head comparison with hormonal therapies and nonhormonal therapies for VMS, assessment of sleep outcomes, and evaluation of efficacy and safety beyond one year are key areas where additional data is still needed.